Under construction – not a live service

Skip to content

Frontlight Research

Trial site

JEM Research Institute

Atlantis, Florida 33462, United StatesNot linked to an institution yet

21running trials
16closed trials

The trials here

What the 37 trials at this site are about, from their registry records.

Conditions: Alzheimer disease27 trials
Obesity5 trials
Type 2 diabetes5 trials
Lewy body dementia2 trials
Chronic kidney disease1 trial
Depression1 trial
Essential tremor1 trial
Frontotemporal dementia1 trial
Multiple sclerosis1 trial
Parkinson disease1 trial
Phase: Phase 320 trials
Phase 212 trials
Phase 11 trial
Status: Active, not recruiting12 trials
Completed11 trials
Recruiting7 trials
Terminated5 trials
Enrolling by invitation1 trial
Not yet recruiting1 trial
Lead sponsor: Eli Lilly and Company15 trials
Cassava Sciences, Inc.2 trials
Cognition Therapeutics2 trials
Cognito Therapeutics, Inc.2 trials
Novartis Pharmaceuticals2 trials
and 13 more

Running trials

Not yet recruiting
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432· Phase 3· Eli Lilly and Company· Source
Contact: David Halpert (principal investigator)
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Contact: Linda Pao (principal investigator)
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595· Phase 2· Eli Lilly and Company· Source
Contact: Linda Pao (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· Phase 3· Eli Lilly and Company· Source
Contact: David Halpert (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Contact: David Halpert (principal investigator)
Active, not recruiting
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· Phase 3· Bristol-Myers Squibb· Source
Contact: Linda Pao, Site 0154
Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321· Phase 2· Lighthouse Pharmaceuticals, Inc.· Source
Contact: Linda Pao, MD
Active, not recruiting
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432· Phase 1· ProMis Neurosciences, Inc· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357· GAP Innovations, PBC· Source
Contact: Erin McBride
Active, not recruiting
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
NCT06223360· Phase 2· Weill Medical College of Cornell University· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173· Phase 2· Acumen Pharmaceuticals· Source
Enrolling by invitation
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
NCT06245031· Cognito Therapeutics, Inc.· Source
Active, not recruiting
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· Phase 3· Eisai Inc.· Source
Active, not recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
NCT02951598· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
NCT06538116· Phase 2· Eli Lilly and Company· Source
Completed
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421· Phase 3· Eli Lilly and Company· Source
Completed
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
NCT05637801· Cognito Therapeutics, Inc.· Source
Terminated
Open-label Extension for Phase 3 Clinical Trials of Simufilam
NCT05575076· Phase 3· Cassava Sciences, Inc.· Source
Completed
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731· Phase 3· Eli Lilly and Company· Source
Terminated
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071· Phase 3· Biogen· Source
Completed
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
NCT05225415· Phase 2· Cognition Therapeutics· Source
Completed
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
NCT05122650· Phase 2· Jazz Pharmaceuticals· Source
Terminated
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT05026177· Phase 3· Cassava Sciences, Inc.· Source
Completed
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
NCT05063539· Phase 2· Eli Lilly and Company· Source
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· Phase 3· Novo Nordisk A/S· Source
Terminated
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
NCT03655236· Phase 2· Sun Pharma Advanced Research Company Limited· Source
Completed
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
NCT03507790· Phase 2· Cognition Therapeutics· Source
Completed
Memory Improvement Through Nicotine Dosing (MIND) Study
NCT02720445· Phase 2· University of Southern California· Source
Terminated
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error

Under construction, not live – JEM Research Institute: trial site – Frontlight Research